Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PREP | P48147 | 5/20 | 0.46 |
| ▸ | DPP4 | P27487 | 13/20 | 0.45 |
| ▸ | DPP8 | Q6V1X1 | 10/20 | 0.43 |
| ▸ | DPP9 | Q86TI2 | 4/20 | 0.42 |
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.42 |
| ▸ | FAP | Q12884 | 2/20 | 0.42 |
| ▸ | CTSS | P25774 | 1/20 | 0.42 |
| ▸ | CTSK | P43235 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL864706 | 1.00 | PREP (0.46) | PREPDPP4DPP8DPP9DPP7 | |
| SCHEMBL864086 | 0.85 | CYP3A4 (0.44) | — | |
| SCHEMBL864087 | 0.85 | CYP3A4 (0.44) | — | |
| SCHEMBL13160656 | 0.81 | CXCR2 (0.43) | CTSSCTSK | |
| SCHEMBL16333118 | 0.81 | CXCR2 (0.43) | CTSSCTSK | |
| SCHEMBL865442 | 0.81 | DPP4 (0.43) | PREPDPP4DPP8DPP9DPP7 | |
| SCHEMBL865440 | 0.81 | DPP4 (0.43) | PREPDPP4DPP8DPP9DPP7 | |
| SCHEMBL865441 | 0.81 | DPP4 (0.43) | PREPDPP4DPP8DPP9DPP7 | |
| SCHEMBL864493 | 0.79 | DPP4 (0.46) | DPP4DPP8DPP9DPP7 | |
| SCHEMBL864492 | 0.79 | DPP4 (0.46) | DPP4DPP8DPP9DPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120077793-A1 | Compounds for the Treatment of Metabolic Disorders | PROSIDION LIMITED (GB) | 2012-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077793-A1 | Compounds for the Treatment of Metabolic Disorders | GPR119, GPR132, FFAR2 | PREP 2627/4885DPP4 217/4885DPP8 615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.